AviadoBio @AviadoBio

We’re heading to #EURETINA2026! Our team will be onsite, connecting with the retina research community & sharing how AviadoBio applies optogenetic #GeneTherapy to our work in IRDs. Attending? Let’s connect. Learn more about our work with optogenetics: aviadobio.com/pipeline/

This World FTD Awareness week, we’re spotlighting the #FrontotemporalDementia community. On their page, Maria Beers and Rachael Martinez of Remember Me share what they wish others knew about FTD from personal experience as caregivers. Learn more here: remembermeftd.com

Thank you to the FTD Brothers for such a meaningful conversation about your family’s experience with FTD and the incredible advocacy work you're doing for the community. Learn more about their important work in #FTD: theftdbrothers.com #FrontotemporalDementia

What stands out about vMiX™? Our proprietary RNAi platform is designed to achieve durable knockdown of disease-driving genes following a single administration, with the goal of addressing the underlying biology of neurodegenerative diseases. Learn more: aviadobio.com/programs/

This #WorldAlzheimersMonth, we recognize the patients, families and caregivers whose lives are drastically changed by Alzheimer’s disease and related dementias. We stand with this community and remain committed to pursuing new possibilities in neurodegenerative disease. #ALZ

#DYK that you can speak with a genetic counselor before inquiring about genetic testing? @KatieBrandt6 tells us more about the importance of connecting with a genetic counselor and how they can help you navigate your personal journey. #GeneticCounseling #FTD

We’ve always been united by one purpose: to create potentially life-changing medicines for people living with neurodegenerative diseases. No matter the role, each team member brings us one step closer to delivering on our promise. Read more: aviadobio.com #TeamCulture

What a week at #AAIC! It was an incredible gathering of minds advancing research in Alzheimer’s disease and related dementias. A highlight for us was sharing data across two programs—AVB-101 targeting FTD and AVB-406 targeting Alzheimer’s & other tauopathies. @alzassociation

20 years ago, our understanding of #FTD changed. In July 2006, researchers established progranulin's central role in FTD — the foundation of our FTD-GRN work today. Thank you to the FTD community moving this mission forward. The most important work is still ahead.

We’re on the ground at #AAIC2026 in London. It’s great to be in the room with so many incredible innovators, researchers, and partners working to advance medicines for patients. Come find us and let’s connect. #ALZ @alzassociation

AAIC 2026 is nearly here in London. Looking forward to time with the Alzheimer's community and learning from the science, clinical progress, and ideas shaping where the field is headed next. #AAIC2026 #AlzheimersDisease @alzassociation

Understanding the genetics of RP is central to developing more precise treatment approaches. AVB-307 is AviadoBio’s investigational gene therapy candidate for RP, designed to address the underlying genetic complexity of the disease. Learn more: aviadobio.com/retinitis-pigm… #RP

AAIC 2026 in London is just around the corner — and our team will be there. We're looking forward to a few days immersed in the latest data, ideas, and dialogue shaping the future of Alzheimer's and related dementias. If you'll be onsite, let's connect. #AAIC2026

We're still at #BIO2026! It's been a great few days of discussion about what’s ahead for AviadoBio. If you're here, let's connect. And if you’re following along from afar, watch this video from our Chief Technology Officer, Alex Bloom, to learn more about our vMiX platform.

We’re looking forward to attending #BIO2026! Our team will be onsite to connect with the broader biotech and life sciences community, share updates on AviadoBio’s pipeline, and engage in conversations shaping the future of our industry. Attending BIO? Let's connect.

This Alzheimer's & Brain Awareness Month, we're standing with the millions of people living with FTD & other neurodegenerative diseases with an urgent need for new approaches. That urgency drives our work every day – with patients and families at the center of everything we do.

Today we announced an expanded exclusive license with @KingsCollegeLon, extending the potential for our vMiX™ platform across all human therapeutic areas. Learn more about this continued partnership and the potential of vMiX: aviadobio.com/expands-vmix-e… #BiotechNews #GeneTherapy

Next week at Drug Discovery Europe 2026, Martina Esposito Soccoio will present our latest development & translational data on AVB-406 — originally presented at ASGCT 2026. If you're attending, stop by to hear more about AVB-406. oxfordglobal.com/discovery-deve… #GeneTherapy #Alzheimers

What does it take to develop transformative gene therapies for neurodegenerative diseases? Our CEO Lisa Deschamps spoke with Onyx Newsroom to share her perspective on what's behind AviadoBio's recent momentum and where we're headed next. Watch now: onyxnewsroom.com/lisa-deschamps…

Our Chief Scientific and Clinical Advisor and Co-founder Chris Shaw is speaking in two sessions this week at the ALS Drug Development Summit in Boston — one on in vitro platforms for ALS drug development, and one on gene silencing approaches for ALS. als-drug-development.com/speaker/christ…